17:35 , Jul 17, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Mouse studies suggest MAPKAPK2 inhibitors could help treat colorectal cancer. In a mouse model of colorectal cancer, systemic MAPKAPK2 knockout decreased tumor number, tumor volume and intestinal polyps and increased survival compared...
20:47 , May 2, 2018 |  BC Innovations  |  Distillery Techniques

Chemistry

TECHNOLOGY: Synthetic chemistry A high throughput, nanomolar-scale chemical synthesis and affinity-ranking platform could enable rapid identification of drug compounds with high binding affinities for their target proteins. The robotics-based platform involves three steps: use of...
22:24 , Apr 24, 2018 |  BC Extra  |  Tools & Techniques

Merck adds affinity optimization to nanoscale synthesis system

A Nature paper from Merck & Co. Inc. (NYSE:MRK) describes a nanoscale synthesis system that incorporates affinity ranking to enable simultaneous product synthesis and characterization of affinity to a target of interest, which could reduce...
07:00 , Jul 16, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Checkpoint kinase 1 (Chk1; CHEK1); MAP kinase-activated protein kinase 2 (MAPKAPK2; MK2); K-Ras (KRAS); BRAF

Cancer INDICATION: Cancer Studies in patient samples and mice suggest combining inhibitors of Chk1 and MAPKAPK2 could help treat KRAS- or BRAF-mutant tumors. In tumor samples from patients with lung or colon adenocarcinomas, levels of...
07:00 , Sep 8, 2014 |  BioCentury  |  Strategy

Parsing Roche's IPF bet

InterMune Inc. 's third Phase III trial transformed it from a forgotten company with $70.3 million in 2013 sales of one Orphan product to a takeout play worth $8.3 billion to Roche . The question...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Clinical News

MMI-0100: Phase I started

Moerae Matrix began a double-blind, placebo-controlled, Dutch Phase I trial to evaluate ascending doses of inhaled MMI-0100 in up to 48 healthy volunteers. MMI-0100 uses MicroDose’s inhaler technology, which uses a piezo vibrator to de-aggregate...
08:00 , Jan 9, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes Calcium calmodulin-dependent protein kinase IIg (CAMK2G) Mouse studies suggest inhibiting CAMK2G could help improve hyperglycemia and insulin sensitivity in patients with type 2...
07:00 , Jul 26, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Inflammation

Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Inflammation; shock/trauma MAP kinase-activated protein kinase 2 (MAPKAPK2; MK2); tumor necrosis factor-a (TNF-a) In vitro and mouse studies suggest a class of MK2 inhibitors could...
07:00 , Jun 25, 2012 |  BC Week In Review  |  Company News

MicroDose Therapeutx, Moerae Matrix deal

The companies partnered to use MicroDose's inhaler technology to develop a dry powder formulation of Moerae's MMI-0100 . The MAP kinase-activated protein kinase 2 ( MAPKAPK2 ; MK2 ) inhibitor is in preclinical testing for...
07:00 , Oct 21, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Spinal cord injury (SCI) MAP kinase-activated protein kinase 2 (MAPKAPK2; MK2) Mouse studies suggest that inhibiting MK2 could help decrease inflammatory damage after SCI. In...